Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock.

Separately, Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $7.24 on Monday. The company has a market cap of $120.98 million, a price-to-earnings ratio of -11.14 and a beta of 0.46. The stock’s 50-day moving average is $7.10 and its two-hundred day moving average is $7.02. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.15. Equities research analysts anticipate that Coya Therapeutics will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Coya Therapeutics

In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of the stock in a transaction dated Monday, November 11th. The stock was bought at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the purchase, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at approximately $36,700. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 12.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Coya Therapeutics

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in Coya Therapeutics in the 3rd quarter valued at about $169,000. Renaissance Technologies LLC acquired a new stake in Coya Therapeutics during the second quarter valued at approximately $101,000. Finally, Gilbert & Cook Inc. bought a new stake in shares of Coya Therapeutics during the 2nd quarter worth $61,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.